A Phase 0/I Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas.
Pankaj B DesaiAniruddha S KarveMisam ZawitPriyanka AroraNimita DaveJoy AwosikaNingjing LiBethany FuhrmanMario MedvedovicLarry SallansAdy KendlerBiplab DasGuptaDavid R PlasRichard CurryMario ZuccarelloRekha ChaudharySoma SenguptaTrisha Michel Wise-DraperPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
On the basis of safety, brain tumoral PK, and mechanistic data, 15 mg daily is identified as the RP2D for future trials.